NYSE:PFEPharmaceuticals
Assessing Pfizer (PFE) Valuation After New PF-3944 Obesity Trial Data And Market Reentry
Pfizer (PFE) is back in the obesity spotlight after reporting Phase 2b VESPER-3 data for its monthly GLP-1 injection, PF-3944, showing up to 12.3% placebo adjusted weight loss at week 28.
See our latest analysis for Pfizer.
The PF-3944 data lands after a busy spell for Pfizer, including better than expected Q4 2025 adjusted earnings, reaffirmed 2026 revenue guidance, a fresh Priority Review for hemophilia drug HYMPAVZI, and ongoing cost and pricing pressures such as TrumpRx agreements. The...